Antibody-drug conjugates (ADCs) represent an emerging class of therapeutics across solid tumor oncology and are already positioned as a cornerstone therapy for patients with urothelial carcinoma (UC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback